Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma

PURPOSE: In primary brain tumors, the efficacy of immune-modulating therapies is still under investigation as inflammatory responses are restricted by tight immunoregulatory mechanisms in the central nervous system. Here, we measured soluble PD-L1 (sPD-L1) in the plasma of patients with recurrent gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Mair, Maximilian J., Ilhan-Mutlu, Ayseguel, Pajenda, Sahra, Kiesel, Barbara, Wöhrer, Adelheid, Widhalm, Georg, Dieckmann, Karin, Marosi, Christine, Wagner, Ludwig, Preusser, Matthias, Berghoff, Anna S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571215/
https://www.ncbi.nlm.nih.gov/pubmed/33956203
http://dx.doi.org/10.1007/s00262-021-02951-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571215/
https://www.ncbi.nlm.nih.gov/pubmed/33956203
http://dx.doi.org/10.1007/s00262-021-02951-2

Ejemplares similares